|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ACOT2 |
Gene summary for ACOT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ACOT2 | Gene ID | 10965 |
| Gene name | acyl-CoA thioesterase 2 | |
| Gene Alias | CTE-IA | |
| Cytomap | 14q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000038 | UniProtAcc | P49753 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10965 | ACOT2 | P38T-E | Human | Esophagus | ESCC | 9.21e-10 | 4.38e-01 | 0.127 |
| 10965 | ACOT2 | P39T-E | Human | Esophagus | ESCC | 7.81e-06 | 9.48e-02 | 0.0894 |
| 10965 | ACOT2 | P40T-E | Human | Esophagus | ESCC | 6.89e-07 | 2.82e-01 | 0.109 |
| 10965 | ACOT2 | P42T-E | Human | Esophagus | ESCC | 1.21e-19 | 4.35e-01 | 0.1175 |
| 10965 | ACOT2 | P44T-E | Human | Esophagus | ESCC | 2.08e-14 | 2.92e-01 | 0.1096 |
| 10965 | ACOT2 | P47T-E | Human | Esophagus | ESCC | 3.19e-15 | 2.03e-01 | 0.1067 |
| 10965 | ACOT2 | P48T-E | Human | Esophagus | ESCC | 5.03e-17 | 2.43e-01 | 0.0959 |
| 10965 | ACOT2 | P49T-E | Human | Esophagus | ESCC | 1.20e-13 | 1.21e+00 | 0.1768 |
| 10965 | ACOT2 | P52T-E | Human | Esophagus | ESCC | 6.64e-13 | 2.80e-01 | 0.1555 |
| 10965 | ACOT2 | P54T-E | Human | Esophagus | ESCC | 1.42e-12 | 3.29e-01 | 0.0975 |
| 10965 | ACOT2 | P56T-E | Human | Esophagus | ESCC | 3.65e-03 | 3.79e-01 | 0.1613 |
| 10965 | ACOT2 | P57T-E | Human | Esophagus | ESCC | 2.51e-23 | 5.12e-01 | 0.0926 |
| 10965 | ACOT2 | P61T-E | Human | Esophagus | ESCC | 2.51e-26 | 7.93e-01 | 0.099 |
| 10965 | ACOT2 | P62T-E | Human | Esophagus | ESCC | 2.26e-32 | 5.59e-01 | 0.1302 |
| 10965 | ACOT2 | P65T-E | Human | Esophagus | ESCC | 2.59e-33 | 7.21e-01 | 0.0978 |
| 10965 | ACOT2 | P74T-E | Human | Esophagus | ESCC | 4.44e-32 | 8.89e-01 | 0.1479 |
| 10965 | ACOT2 | P75T-E | Human | Esophagus | ESCC | 8.76e-56 | 1.00e+00 | 0.1125 |
| 10965 | ACOT2 | P76T-E | Human | Esophagus | ESCC | 5.28e-22 | 4.24e-01 | 0.1207 |
| 10965 | ACOT2 | P79T-E | Human | Esophagus | ESCC | 1.68e-39 | 6.71e-01 | 0.1154 |
| 10965 | ACOT2 | P80T-E | Human | Esophagus | ESCC | 5.64e-12 | 2.66e-01 | 0.155 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
| GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
| GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
| GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
| GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
| GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
| GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
| GO:0006631 | Colorectum | AD | fatty acid metabolic process | 114/3918 | 390/18723 | 5.58e-05 | 9.44e-04 | 114 |
| GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
| GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0033875 | Colorectum | AD | ribonucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:0034032 | Colorectum | AD | purine nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
| GO:00061631 | Colorectum | SER | purine nucleotide metabolic process | 109/2897 | 396/18723 | 4.26e-10 | 5.44e-08 | 109 |
| GO:00091501 | Colorectum | SER | purine ribonucleotide metabolic process | 103/2897 | 368/18723 | 4.69e-10 | 5.68e-08 | 103 |
| GO:00725211 | Colorectum | SER | purine-containing compound metabolic process | 113/2897 | 416/18723 | 4.80e-10 | 5.68e-08 | 113 |
| GO:00092591 | Colorectum | SER | ribonucleotide metabolic process | 104/2897 | 385/18723 | 3.27e-09 | 3.04e-07 | 104 |
| GO:00196931 | Colorectum | SER | ribose phosphate metabolic process | 105/2897 | 396/18723 | 8.15e-09 | 7.14e-07 | 105 |
| GO:00091171 | Colorectum | SER | nucleotide metabolic process | 122/2897 | 489/18723 | 2.50e-08 | 1.76e-06 | 122 |
| GO:00067531 | Colorectum | SER | nucleoside phosphate metabolic process | 122/2897 | 497/18723 | 6.64e-08 | 4.33e-06 | 122 |
| GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa00062 | Colorectum | SER | Fatty acid elongation | 11/1580 | 27/8465 | 6.38e-03 | 3.68e-02 | 2.67e-02 | 11 |
| hsa000621 | Colorectum | SER | Fatty acid elongation | 11/1580 | 27/8465 | 6.38e-03 | 3.68e-02 | 2.67e-02 | 11 |
| hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa010402 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
| hsa010403 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ACOT2 | SNV | Missense_Mutation | c.875N>A | p.Gly292Glu | p.G292E | P49753 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACOT2 | SNV | Missense_Mutation | rs775410758 | c.620G>C | p.Arg207Pro | p.R207P | P49753 | protein_coding | deleterious(0.01) | benign(0.238) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| ACOT2 | SNV | Missense_Mutation | novel | c.887N>T | p.Gly296Val | p.G296V | P49753 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A8EC-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
| ACOT2 | SNV | Missense_Mutation | c.26N>G | p.His9Arg | p.H9R | P49753 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| ACOT2 | SNV | Missense_Mutation | novel | c.194C>T | p.Ala65Val | p.A65V | P49753 | protein_coding | tolerated(0.55) | benign(0.015) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| ACOT2 | SNV | Missense_Mutation | c.203N>G | p.Ile68Ser | p.I68S | P49753 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ACOT2 | SNV | Missense_Mutation | c.26A>G | p.His9Arg | p.H9R | P49753 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ACOT2 | SNV | Missense_Mutation | novel | c.133C>A | p.Leu45Met | p.L45M | P49753 | protein_coding | tolerated(0.22) | benign(0.094) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| ACOT2 | SNV | Missense_Mutation | rs765220557 | c.46A>G | p.Arg16Gly | p.R16G | P49753 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ACOT2 | SNV | Missense_Mutation | novel | c.63G>A | p.Met21Ile | p.M21I | P49753 | protein_coding | tolerated_low_confidence(0.23) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |